Second collaboration builds on rapid progress of AI-designed KAT6 inhibitor licensed in 2024 Agreement includes $20 million upfront payment with potential total value exceeding $550 million plus tiered royalties New preclinical asset demonstrates broad anti-tumor activity across multiple solid tumor types Less than a year after their first collaboration, pharmaceutical giant Menarini Group and AI-driven…